InvestorsHub Logo
Followers 800
Posts 50862
Boards Moderated 2
Alias Born 12/12/2004

Re: None

Thursday, 05/12/2022 9:52:06 AM

Thursday, May 12, 2022 9:52:06 AM

Post# of 55
BridgeBio Eligible To Receive Up To $905M From Bristol Myers Squibb In Agreement
7:33 am ET May 12, 2022 (Benzinga) Print

- BridgeBio is eligible to receive up to $905 million, including an upfront payment of $90 million, and up to $815 million in additional milestone payments and royalties


-SHP2 inhibitor deal expands earlier agreement between BridgeBio and Bristol Myers Squibb to study BBP-398 in combination with OPDIVO® (nivolumab) in advanced solid tumors with KRAS mutations



- BridgeBio will continue to lead its three current Phase 1 monotherapy and BBP-398 combination therapy trials with additional support from Bristol Myers Squibb; future clinical trials will be performed and funded by Bristol Myers Squibb

New York Yankees and Duke Basketball

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BBIO News